z-logo
open-access-imgOpen Access
Longitudinal study of surrogate aging measures during human immunodeficiency virus seroconversion
Author(s) -
Janice M. Leung,
Nick Fishbane,
Meaghan J. Jones,
Alexander M. Morin,
Stella Xu,
Joseph CY Liu,
Julie L. MacIsaac,
MJ Milloy,
Kanna Hayashi,
Julio Montaner,
Steve Horvath,
Michael S. Kobor,
Don D. Sin,
P. Richard Harrigan,
S.F. Paul Man
Publication year - 2017
Publication title -
aging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.473
H-Index - 90
ISSN - 1945-4589
DOI - 10.18632/aging.101184
Subject(s) - seroconversion , telomere , methylation , cpg site , dna methylation , human immunodeficiency virus (hiv) , polymerase chain reaction , dried blood spot , real time polymerase chain reaction , biology , virology , immunology , medicine , genetics , dna , gene , gene expression
Persons living with human immunodeficiency virus (HIV) harbor an increased risk of age-related conditions. We measured changes in telomere length and DNA methylation in the peripheral blood of 31 intravenous drug users, who were followed longitudinally with blood samples pre-HIV (T1), immediately post-HIV (T2; 1.9±1 year from T1), and at a later follow-up time (T3; 2.2±1 year from T2). Absolute telomere length measurements were performed using polymerase chain reaction methods. Methylation profiles were obtained using the Illumina Human Methylation450 platform. Methylation aging was assessed using the Horvath method. Telomere length significantly decreased between T1 and T2 (227±46 at T1 vs. 201±48 kbp/genome at T2, p=0.045), while no differences were observed between T2 and T3 (201±48 at T2 vs. 186±27 kbp/genome at T3, p=0.244). Methylation aging as measured by the age acceleration residual increased over the time course of HIV infection (p=0.035). CpG sites corresponding to PCBP2 and CSRNP1 were differentially methylated between T1 and T2 at a q-value <0.05. Telomere shortening and methylation changes can therefore be observed in the short-term period immediately following HIV seroconversion. Further studies to confirm these results in larger sample sizes and to compare these results to non-HIV and non-injection drug users are warranted.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom